Cover Image
市場調查報告書

培養皮膚 (皮膚替代品) 市場預測:各類型 (無細胞,同類細胞,自體細胞等),各用途,各地區

Tissue Engineered - Skin Substitutes Market: By Type (Acellular, Cellular Allogeneic, Cellular Autologous, Others); By Application (Burn Injury, Diabetic/Vascular Ulcer and Others); & By Region - (2016-2022)

出版商 IndustryARC 商品編碼 422696
出版日期 內容資訊 英文 142 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
培養皮膚 (皮膚替代品) 市場預測:各類型 (無細胞,同類細胞,自體細胞等),各用途,各地區 Tissue Engineered - Skin Substitutes Market: By Type (Acellular, Cellular Allogeneic, Cellular Autologous, Others); By Application (Burn Injury, Diabetic/Vascular Ulcer and Others); & By Region - (2016-2022)
出版日期: 2017年09月14日 內容資訊: 英文 142 Pages
簡介

本報告提供全球培養皮膚 (皮膚替代品) 市場相關調查分析,提供市場形勢,市場動態,策略性分析,市場分析 (各市場區隔),再加上主要企業等相關的系統性資訊。

第1章 培養皮膚 (皮膚替代品) 市場:概要

第2章 摘要整理

第3章 培養皮膚 (皮膚替代品) 市場:形勢

  • 市場佔有率分析
  • 比較分析
  • 產品基準
  • 終端用戶簡介
  • 財務分析前五名

第4章 培養皮膚 (皮膚替代品) 市場:動態

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題
  • 波特的五力分析

第5章 培養皮膚 (皮膚替代品) 市場:策略性分析

  • 價值鏈分析
  • 價格分析
  • 機會分析
  • 產品/市場生命週期分析
  • 供給業者·經銷商

第6章 培養皮膚 (皮膚替代品) 市場:各類型

  • 無細胞
  • 同類細胞
  • 自體細胞
  • 其他

第7章 培養皮膚 (皮膚替代品) 市場:各用途

  • 燒燙傷
  • 糖尿病性/血管性潰瘍
  • 其他

第8章 培養皮膚 (皮膚替代品) 市場:各地區

  • 歐洲
  • 亞太地區
  • 北美
  • 其他

第9章 培養皮膚 (皮膚替代品) 市場:熵

第10章 企業簡介

  • Acelity L.P., Inc.
  • BSN medical
  • Integra LifeSciences Corporation
  • Medtronic (Covidien)
  • Molnlycke Health Care
  • Smith & Nephew plc
  • Organogenesis, Inc.
  • ConVatec
  • 3m Healthcare
  • Integra LifeSciences Corporation

第11章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Skin substitutes are cellular and acellular material which help in aiding in the healing of damaged skin by releasing cytokines and growth factors at the wound site. These skin substitutes or artificial skin substitute are derived from human tissue, non-human tissue, synthetic materials, and combination of the above materials and are grafted on the injured part. Globally, growing cases of skin related injuries and growing medical tourism to low cost destinations is expected to remain one of the key growth driver during the period of study.

Geographically, North America dominated the tissue engineered - skin substitutes market driven by world class healthcare infrastructure with technological advanced practice, higher spending and presence of key industry players in the region. North America was followed by Europe and Asia-Pacific as second and third largest market for tissue engineered - skin substitutes market. Asia Pacific is projected to have the fastest growth, owing to rapidly developing medical infrastructure, increasing spending on healthcare and growing medical tourism in developing nations such as China and India in this region.

This report identifies the tissue engineered - skin substitutes market size for the years 2014-2016, and forecast of the same till the year 2022. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to the tissue engineered - skin substitutes market.

This report segments the tissue engineered - skin substitutes market on the basis of type, application and regional market as follows:

Tissue Engineered - Skin Substitutes market research report is classified on the basis of type. Some of the major types covered in this report are as follows: Acellular, Cellular Allogeneic, Cellular Autologous, Others.

Tissue Engineered - Skin Substitutes market research report is classified on the basis of application. Some of the major applications covered in this report are as follows: Burn Injury, Diabetic/Vascular Ulcer and Others.

This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region.

This report identifies all the major companies operating in the tissue engineered - skin substitutes market. Some of the major companies' profiles in detail are as follows:

Acelity L.P., Inc.

BSN medical

Integra LifeSciences Corporation

Medtronic (Covidien)

Molnlycke Health Care

1. Tissue Engineered - Skin Substitutes Market - Overview

2. Executive Summary

3. Tissue Engineered - Skin Substitutes Market Landscape

  • 3.1. Market Share Analysis
  • 3.2. Comparative Analysis
  • 3.3. Product Benchmarking
  • 3.4. End User Profiling
  • 3.5. Top 5 Financials Analysis

4. Tissue Engineered - Skin Substitutes Market- Forces

  • 4.1. Drivers
    • 4.1.1. Rise in Geriatric Population
    • 4.1.2. Increasing Incidence rate of Skin disorders
  • 4.2. Restraints
    • 4.2.1. High cost
  • 4.3. Opportunities
  • 4.4. Challenges
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of New Entrants
    • 4.5.4. Threat of Substitutes
    • 4.5.5. Degree of Competition

5. Tissue Engineered - Skin Substitutes Market- Strategic Analysis

  • 5.1. Value Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Opportunities Analysis
  • 5.4. Product/Market Life Cycle Analysis
  • 5.5. Suppliers and Distributors

6. Tissue Engineered - Skin Substitutes Market, By Type

  • 6.1. Acellular
  • 6.2. Cellular Allogeneic
  • 6.3. Cellular Autologous
  • 6.4. Others

7. Tissue Engineered - Skin Substitutes Market, By Application

  • 7.1. Burn Injury
  • 7.2. Diabetic/Vascular Ulcer
  • 7.3. Others

8. Tissue Engineered - Skin Substitutes Market, By Geography

  • 8.1. Europe
    • 8.1.1. Germany
    • 8.1.2. France
    • 8.1.3. Italy
    • 8.1.4. Spain
    • 8.1.5. Russia
    • 8.1.6. U.K.
    • 8.1.7. Rest of Europe
  • 8.2. Asia Pacific
    • 8.2.1. China
    • 8.2.2. India
    • 8.2.3. Japan
    • 8.2.4. South Korea
    • 8.2.5. Rest of Asia-Pacific
  • 8.3. North America
    • 8.3.1. U.S.
    • 8.3.2. Canada
    • 8.3.3. Mexico
  • 8.4. Rest of the World (RoW)
    • 8.4.1. Brazil
    • 8.4.2. Rest of RoW

9. Tissue Engineered - Skin Substitutes Market - Entropy

  • 9.1. Expansion
  • 9.2. Technological Developments
  • 9.3. Merger & Acquisitions, and Joint Ventures
  • 9.4. Supply- Contract

10. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)

  • 10.1. Acelity L.P., Inc.
  • 10.2. BSN medical
  • 10.3. Integra LifeSciences Corporation
  • 10.4. Medtronic (Covidien)
  • 10.5. Molnlycke Health Care
  • 10.6. Smith & Nephew plc
  • 10.7. Organogenesis, Inc.
  • 10.8. ConVatec
  • 10.9. 3m Healthcare
  • 10.10. Integra LifeSciences Corporation

More than 40 Companies are profiled in this Research Report, Complete List available on Request*

"*Financials would be provided on a best efforts basis for private companies"

11. Appendix

  • 11.1. Abbreviations
  • 11.2. Sources
  • 11.3. Research Methodology
  • 11.4. Bibliography
  • 11.5. Compilation of Expert Insights
  • 11.6. Disclaimer
Back to Top